China Biotech Services swings to FY26 H1 profit of HK$ 15.06 million; revenue rises 49.7% to HK$ 37.23 million

• China Biotech Services posted a swing to profit of HK$15.06 million in the six months ended June 30, from a loss a year earlier.
• Revenue rose 49.7% to HK$37.23 million, driven by BNCT services revenue of HK$26.72 million following trial operations starting in February 2026.
• Operating loss widened to HK$31.16 million from HK$6.79 million, while a fair value gain on derivative financial liabilities totaled HK$84.23 million.
• Finance costs climbed to HK$26.92 million from HK$12.46 million, mainly tied to the US$35 million 2026 Convertible Bonds issued in February.
• Insurance brokerage revenue fell to HK$8.52 million from HK$22.64 million after Hong Kong referral-fee limits took effect on Oct. 1, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12307074), on August 28, 2026, and is solely responsible for the information contained therein.